<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8748</journal-id>
<journal-title><![CDATA[Acta Neurológica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Neurol Colomb.]]></abbrev-journal-title>
<issn>0120-8748</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87482010000400005</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Atypical acute inflammatory demyelinating polyneuropathy in the setting of HIV infection: Report of two cases]]></article-title>
<article-title xml:lang="es"><![CDATA[Polineuropatia desmielinizante aguda en SIDA: presentación de dos casos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bernal-Cano]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[Jorge O]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Carlos A]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lowenstein]]></surname>
<given-names><![CDATA[Ellen]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valderrama]]></surname>
<given-names><![CDATA[Sandra L]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Carlos H]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tamara]]></surname>
<given-names><![CDATA[Jose R]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Universitario de San Ignacio Division of Infectious Diseases  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2010</year>
</pub-date>
<volume>26</volume>
<numero>4</numero>
<fpage>210</fpage>
<lpage>214</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87482010000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87482010000400005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87482010000400005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Acute inflammatory demyelinating polyneuropathy AIDP is an immune mediated disorder that affects the peripheral nerve reflected in myelin damage and sometimes in axonal loss. Upper respiratory infection, gas- trointestinal infection or nonspecific febrile processes are clinical entities that usually precede neurological symptoms represented by progressive weakness of the extremities and attenuation of tendinous reflexes. In the setting of HIV infection AIDP is a peripheral nerve disorder that usually occurs shortly after seroconversion when the CD4 count is higher than 500 cells/µl. It is presumed to be immune mediated, although the offending antibody has not been identified yet. We report two clinical cases of atypical AIDP in the setting of HIV infection: The first with a T lymphocyte CD4 count lower than 100 cells /µl and the second in context of immunologic reconstitution inflammatory syndrome IRIS. Both entities are uncommon phenomena. The patients recovered satisfactorily after receiving intravenous immunoglobulin and temporary cessation of antiretroviral therapy respectively.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[La polineuropatia desmielinizante aguda (AIDP) es un desorden inmune que afecta el nervio periférico produciendo lesión axonal o mielínica. las infecciones respiratorias altas, gastrointestinales o los cuadros febriles inespecíficos usualmente preceden este caudro clínico caracterizado por debilidad progresiva y disminución de reflejos miotendinosos. En el paciente con infección VIH la AIDP usulamnete aparece en el periodo de seroconversión cuando el conteo de CD4 es mayor a 500 células/uL. Se presume origen infecciosos a pesar de no existir un anticuerpo específico. reportamos dos casos de paciente con VIH y ADPI con resentación atípica. El primero con un conteo de CD4 menos a 100 células/uL, el segundo en el contexto de síndrome de reconstitución inmunológica (IRIS). Ambos pacientes tuvieron recuperación satisfactoria luego de tratamiento con inmunoglobulina intravenosa y suspensión temporal del tratamiento antiretroviral respectivamente.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[Polyneuropathies]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de inmunodeficiencia adquirida]]></kwd>
<kwd lng="es"><![CDATA[Polineuropatias]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[   <font face="verdana" size="2">     <p align="center"><font size="3" face="verdana"><b>Atypical acute inflammatory demyelinating    polyneuropathy in the setting of HIV infection:    Report of two cases </b></font></p>     <p align="center"><font size="3" face="verdana"><b>Polineuropatia desmielinizante aguda en SIDA:  presentaci&oacute;n de dos casos</b></font></p>     <p align="center">&nbsp;</p> </font>    <p align="center"><font size="2" face="verdana">    <br>   Francisco Bernal-Cano, MD; Jorge O Su&aacute;rez, MD MSc; Carlos A &Aacute;lvarez, MD MSc  Ellen Lowenstein, MD; Sandra L Valderrama,     <br>   MD; Carlos H G&oacute;mez, M.D; Jose R Tamara, MD. Affiliation: Hospital Universitario de San Ignacio Division of Infectious Diseases.Correo electr&oacute;nico: <a href="mailto:bernal.f@javeriana.edu.co">bernal.f@javeriana.edu.co</a> </font></p> <font face="verdana" size="2">    <p align="center">&nbsp;</p>     <p align="left">Recibido: 14/07/10. Revisado: 14/07/10. Aceptado: 30/07/10. </p><hr size="3 ">     <p>&nbsp;</p> </font>  <hr size="3">   </p> </font>     ]]></body>
<body><![CDATA[<p><font size="3" face="verdana"><b>SUMMARY</b></font></p> <font face="verdana" size="2">     <p> Acute inflammatory demyelinating polyneuropathy AIDP is an immune mediated disorder that affects the      peripheral nerve reflected in myelin damage and sometimes in axonal loss. Upper respiratory infection, gas-     trointestinal infection or nonspecific febrile processes are clinical entities that usually precede neurological     symptoms represented by progressive weakness of the extremities and attenuation of tendinous reflexes.  In      the setting of HIV infection AIDP is a peripheral nerve disorder that usually occurs shortly after seroconversion when the CD4 count is higher than 500 cells/&micro;l. It is presumed to be immune mediated, although the      offending antibody has not been identified yet. We report two clinical cases of atypical AIDP in the setting      of HIV infection:  The first with a T lymphocyte CD4 count lower than 100 cells /&micro;l and the second in context of immunologic reconstitution inflammatory syndrome IRIS. Both entities are uncommon phenomena.      The patients recovered satisfactorily after receiving intravenous immunoglobulin and temporary cessation of  antiretroviral therapy respectively.</p> </font>     <p><font size="2" face="verdana"><b> <font size="3">KEY WORDS</font>.</b> HIV, Polyneuropathies. </font></p> <font face="verdana" size="2"> <hr size="3">     <p><font size="3" face="verdana"><b>RESUMEN</b></font></p> <font face="verdana" size="2">     <p>La polineuropatia desmielinizante aguda (AIDP) es un desorden inmune que afecta el nervio perif&eacute;rico produciendo    lesi&oacute;n axonal o miel&iacute;nica. las infecciones respiratorias altas, gastrointestinales o los cuadros febriles inespec&iacute;ficos    usualmente preceden este caudro cl&iacute;nico caracterizado por debilidad progresiva y disminuci&oacute;n de reflejos miotendinosos. En el paciente con infecci&oacute;n VIH la AIDP usulamnete aparece en el periodo de seroconversi&oacute;n cuando    el conteo de CD4 es mayor a 500 c&eacute;lulas/uL. Se presume origen infecciosos a pesar de no existir un anticuerpo    espec&iacute;fico. reportamos dos casos de paciente con VIH y ADPI con resentaci&oacute;n at&iacute;pica. El primero con un conteo    de CD4 menos a 100 c&eacute;lulas/uL, el segundo en el contexto de s&iacute;ndrome de reconstituci&oacute;n inmunol&oacute;gica (IRIS).    Ambos pacientes tuvieron recuperaci&oacute;n satisfactoria luego de tratamiento con inmunoglobulina intravenosa y  suspensi&oacute;n temporal del tratamiento antiretroviral respectivamente.</p> </font>     <p><font size="2" face="verdana"><b> <font size="3">PALABRAS CLAVES.</font></b> S&iacute;ndrome de inmunodeficiencia adquirida, Polineuropatias.     <br> </font> <font face="verdana" size="2"> <hr>       <p><b>Case reports</b>    <br>   <b>Patient 1</b></p>     <p>    A 37 year old male diagnosed with human immunodeficiency virus (HIV) infection in september      2008 whose initial T lymphocyte CD4 count was 20      cells/&micro;l on antiretroviral therapy with zidovudine,      lamivudine and nevirapine started on mid october,      presented in early february 2009 with a one week      history of rapid progressive strength and sensory      loss on lower extremities with further involvement      of both hands. On admission to the hospital the neurological examination disclosed proximal and distal      reduced strength which Medical Research Council      (MRC) score was 3/5. In addition, tendinous reflexes      were absent and severe sensory loss for all modalities      was noted on stocking distribution. By this time his      T lymphocyte CD4 count was 46 cells per micro      liter and HIV viral load was lower than 40 copies/     ml. Other serum test included complete blood count    (CBC), liver enzymes, renal and thyroid profile,    vitamin B12, folic acid, lactate and creatin kinase    (CK) determinations which results were reported as    normal. Cerebrospinal fluid (CSF) analysis showed    0 cells, protein 231 mg/dl and glucose 66mg/dl.    Cultures for bacteria, fungus and deoxyribonucleic    acid (DNA) polymerase chain reaction (PCR) for    cytomegalovirus (CMV) varicella zoster virus (VZV)    and tuberculosis were negative. Additionally CSF    venereal disease research laboratory (VDRL) was    non reactive and CSF HIV viral load was lower    than 200 copies/ml. A diagnosis of Guillain Barre    syndrome was made further supported by nerve    conduction study and electromyography of four    limbs that demonstrated demyelination with reduced    motor conduction velocities and prolonged distal    motor latencies. Furthermore F wave responses were    markedly reduced and EMG showed reduction in    motor unit recruitment. (<a href="#fig1">Figure 1</a>) The patient was    commenced on a five-day course of intravenous    immunoglobulin (IVIG) in a dose of 0.4 g/kg    body weight a day with no side effects. The patient    started improving his neurological condition shortly    after completion of IVIG administration, reaching    complete recovery following two months. During    all this time the patient continued his antiretroviral  regimen with no changes.</p>     ]]></body>
<body><![CDATA[<p align="center"><a name="fig1"></a><img src="img/revistas/anco/v26n4/v26n4a05fig1.jpg"></p>       <p><b>Patient 2</b></p>       <p>    A 46 year old male with HIV infection diagnosed      in February 25, 2008 in the setting of P. Jirovecci      pneumonia, T lymphocyte CD4 count of 49 cells/&micro;l and HIV viral load higher than 1000000 copies      /ml, started antiretroviral therapy with zidovudine,      lamivudine and efavirenz in the third week of March      08. He noted one month later a six days history of      difficulty to walk due to loss of strength on both      lower extremities with no sensory involvement.      Other medications included trimethoprim sulfamethoxasole and fluconazol. On admission to the      hospital his physical examination only showed mild      quadriparesis with absent achillean and patellar      reflexes. Workup laboratories included CBC, electrolytes, liver enzymes, renal function, thyroid profile,      vitamin B12, folic acid, and lactate, all reported as      normal. In addition his most recent T lymphocyte      CD4 count was 221 cells/&micro;l and the HIV viral load      was lower than 50 copies /ml. CSF analysis showed      1 cell, protein 157 mg/dl and glucose 54 mg/dl,      cultures were negative; VDRL non reactive and      CMV/VZV DNA detection by PCR was negative.      CSF HIV viral load was lower than 200 copies per      ml. One week later nerve conduction studies plus      EMG of lower extremities were done showing      reduced F waves responses and motor conduction      velocities. EMG showed only mild reduction in      motor unit recruitment (<a href="#fig2">Figure 2</a>). A diagnosis of      acute inflammatory demyelinating polyneuropathy      (AIDP) in the setting of an immune reconstitution      syndrome was made. Because the symptoms were      not disabling the patient severely at all, it was decided      to continue with his antiretroviral regimen without      modification. No further worsening of symptoms      was noted by the patient and his neurological examination showed a rapid improvement of the strength      one month after starting an intensive program of      physical therapy. Currently -June 2009- he has no    neurological symptoms.</p>          <p align="center"><a name="fig2"></a><img src="img/revistas/anco/v26n4/v26n4a05fig2.jpg"></p ></font>     <p><font size="3" face="verdana"><b>DISCUSSION</b></font></p> <font face="verdana" size="2">       <p>    Cell-mediated immunity is known to play an      important role in the pathogenesis of GBS. The cha-   racteristic initial stage of this entity is associated with demyelinization related to the action of macrophages, with multifocal distribution in the nerves. The    main action of T cells appears to be the impairment    of the integrity of the blood-nerve barrier by the    action of metalloproteinases, in addition to influence    the recruitment of other immune cells o such as    macrophages, Schwann cells and fibroblasts (1).    Acute AIDP is an uncommon disorder in the setting of HIV infection that usually has been seen shortly    after seroconversion when the T lymphocyte CD4    count is higher than 500 cells/&micro;l (2), this disorder    seems to be immune mediated depending on a    possible over activity of T and B lymphocyte cell    population. Biopsy and autopsy findings have been    contradictory regarding the presence or absence of    perivascular lymphocyte infiltration in GBS. The fact that no lymphocytes are detected in nerves    suggests that the changes mediated by antibodies    are important, in agreement with the pathogenetic    mechanism proposed for the onset of GBS, which    occurs after infections, as is the case or Campylobacter jejuni which is associated with antibodies to    GM1 and GQ1b gangliosides. These gangliosides    share epitopes with the lipopolysaccharide coat of    some strains of this bacterium (3). </p>          <p>    There are few HIV/AIDP cases published in the      literature whose CD4 count is lower than 50 cells      and co infection especially by cytomegalovirus has      been ruled out either by CSF DNA detection by PCR      or clinical course.2, 4 The exact mechanism of thiphenomenon is unknown since it could be assumed      that patients with not enough T lymphocyte CD4      count are unable to mount a competent immune      response. However it is hypothesized that alteration      of T cell homeostasis induced lymphopenia could      be permissive for the disruption of self tolerance      and autoimmune disease may occur in lymphopenic  patients (4). </p>       <p>The first case is an example of this scenario      which clinical outcome behaved similar to Guillain     Barre syndrome in HIV seronegative patients that      usually respond to IVIG or lasmapheresis (5).      Some authors promote performing plasmapheresis followed by IVIG in the setting of HIV infection      but cases where the CD4 count is lower than 100      cells /&micro;l administration of gancyclovir or foscarnet      should be considered until CMV polyradiculopathy    is excluded (6).</p>       <p>    The second case displays an immune reconstitution syndrome (7) that elicited AIDP in context of      recent onset of antiretroviral therapy with a CD4      count lower than 100 cells/&micro;l. In this situation an      autoimmune disorder can promotes damage of      peripheral nerves explained by the role of T cells      contributing to the selection of natural self-reactive      antibody repertories whose expression of immuoglobulin M (IgM) and immunoglobulin G (IgG)      toward some self-antigens depends on the number      of T CD4 lymphocytes (8). </p>       <p>    The course of HIV is characterised by a decreasing CD4 count and a rising viral load. There is loss      of lymphocytes to a level where secondary immune      responses are lost to both primary and recall      antigens.9 On commencement of HAART viral      suppression is sufficient to allow regeneration, by      clonal expansion of the remaining clones, of these      immune responses.10 This has resulted in an immunological response to self or pathogen, where there      was previously anergy, the aptly named immune      reconstitution syndrome.11,12. To our knowledge      there are no more than 10 case reports published      of AIDP associated to immunologic reconstitution      inflammatory syndrome (IRIS) in the setting of HIV      infection (9-12). Therapeutic approaches include conservative measures, steroids plasmapheresis or      temporary suspension of antiretroviral therapy (12).</p>       ]]></body>
<body><![CDATA[<p><b>    Acknowledgments</b></p>       <p>     Special thanks are given to to Pontificia Universidad Javeriana school of Medicine, Dr Joe Fernando Mu&ntilde;oz for his clinical work and  editorial assistance      and Dr Julio Cesar Castellanos, for supporting      Infectious Diseases Unit at Hospital Universitario  de San Ignacio in Bogota Colombia South America. </p> </font>     <p>&nbsp;</p>     <p><font size="3" face="verdana"><b>REFERENCES:</b></font></p> <font face="verdana" size="2">       <!-- ref --><p>    <b>1.  PITHADIA AB, KAKADIA N.</b> Guillain-Barr&eacute;      syndrome (GBS). Pharmacol Rep. 2010; 62: 220-32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000037&pid=S0120-8748201000040000500001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b> 2. BRANNAGAN TH 3RD, ZHOU Y. HIV</b>-associated Guillain-Barre syndrome. J Neurol Sci. 2003: 15; 208: 39-42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000039&pid=S0120-8748201000040000500002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>    <b>3. QURESHI AI, COOK AA, MISHU H, KREN   DEL DA.</b> Guillain- Barre&acute; syndrome in immunocompromised patients: a report of three patients      and review of the literature. Muscle Nerve. 1997; 20:      1002-1007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000041&pid=S0120-8748201000040000500003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p><b>    4. MISHRA BB, SOMMERS W, KOSKI CL,    GREENSTEIN JI</b>. Acute inflammatory demyelinating polyneuropathy in the acquired immune deficiency syndrome.  Ann Neurol. 1985; 18: 131-132.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000043&pid=S0120-8748201000040000500004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>       <!-- ref --><p><b> 5. KRUPICA JR T, FRY TJ, MACKALL CL.</b> Autoimmunity during lymphopenia: a two-hit model. Clin      Immunol. 2006; 2: 121-128.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000045&pid=S0120-8748201000040000500005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b> 6. BURNS TM.</b> Guillain-Barre syndrome. Semin      Neurol. 2008; 28: 152-67.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000047&pid=S0120-8748201000040000500006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b>    7. MARKARIAN Y, WULFF EA, SIMPSON DM. </b>    Peripheral neuropathy in HIV disease. AIDS Clin      Care. 1998;10:89-91, 93, 98.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000049&pid=S0120-8748201000040000500007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b> 8. SHELBURNE SA 3RD, HAMILL RJ.</b> The      immune reconstitution inflammatory syndrome.      AIDS Rev. 2003; 5: 67-79.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000051&pid=S0120-8748201000040000500008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p><b> 9. STAHL D, LACROIX-DESMAZES S, MISRA N,    KARMOCHKINE M, KAVERI SV, COSTAGLIOLA    D, ET AL</b>. Alterations of self-reactive antibody      repertoires in HIV disease: an insight into the role      of  T cells in the selection of autoreactive B cells.      Immunol Lett. 2005; 99: 198-208.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000053&pid=S0120-8748201000040000500009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b>    10. TEO EC, AZWRA A, JONES RL, GAZZARD    BG, NELSON M.</b> Guillain--Barre syndrome following immune reconstitution after antiretroviral      therapy for primary HIV infection. J HIV Ther.      2007; 12: 62-63.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000055&pid=S0120-8748201000040000500010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p><b>    11. FUJISAKI G, KAMI M, MURASHIGE N, KISHI    Y, HORI A, CHIZUKA A.</b> Guillain-Barre syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell      transplantation. Bone Marrow Transplant. 2006; 37:      617-619.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000057&pid=S0120-8748201000040000500011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p>       <!-- ref --><p><b>    12. PILIERO PJ, FISH DG, PRESTON S, CUNNINGHAM D, KINCHELOW T, SALGO M, ET    AL.</b> Guillain-Barr&eacute; syndrome associated with      immune reconstitution. Clin Infect Dis. 2003; 36:      e1111-114.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000059&pid=S0120-8748201000040000500012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </p> </font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PITHADIA]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[KAKADIA]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barré syndrome (GBS)]]></article-title>
<source><![CDATA[Pharmacol Rep.]]></source>
<year>2010</year>
<volume>62</volume>
<page-range>220-32</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRANNAGAN]]></surname>
<given-names><![CDATA[TH 3RD]]></given-names>
</name>
<name>
<surname><![CDATA[ZHOU]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[HIV-associated Guillain-Barre syndrome]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2003</year>
<volume>208</volume>
<page-range>39-42</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[QURESHI]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[COOK]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[MISHU]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[KREN]]></surname>
<given-names><![CDATA[DEL DA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barre´ syndrome in immunocompromised patients: a report of three patients and review of the literature]]></article-title>
<source><![CDATA[Muscle Nerve.]]></source>
<year>1997</year>
<volume>20</volume>
<page-range>1002-1007</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MISHRA]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[SOMMERS]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[KOSKI]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[GREENSTEIN]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute inflammatory demyelinating polyneuropathy in the acquired immune deficiency syndrome]]></article-title>
<source><![CDATA[Ann Neurol.]]></source>
<year>1985</year>
<volume>18</volume>
<page-range>131-132</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KRUPICA]]></surname>
<given-names><![CDATA[JR T]]></given-names>
</name>
<name>
<surname><![CDATA[FRY]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[MACKALL]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autoimmunity during lymphopenia: a two-hit model]]></article-title>
<source><![CDATA[Clin Immunol.]]></source>
<year>2006</year>
<volume>2</volume>
<page-range>121-128</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BURNS]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barre syndrome]]></article-title>
<source><![CDATA[Semin Neurol.]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>152-67</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MARKARIAN]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[WULFF]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[SIMPSON]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Peripheral neuropathy in HIV disease]]></article-title>
<source><![CDATA[AIDS Clin Care.]]></source>
<year>1998</year>
<volume>10</volume>
<page-range>89-91, 93, 98</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SHELBURNE]]></surname>
<given-names><![CDATA[SA 3RD]]></given-names>
</name>
<name>
<surname><![CDATA[HAMILL]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The immune reconstitution inflammatory syndrome]]></article-title>
<source><![CDATA[AIDS Rev.]]></source>
<year>2003</year>
<volume>5</volume>
<page-range>67-79</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[STAHL]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[LACROIX-DESMAZES]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[MISRA]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[KARMOCHKINE]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[KAVERI]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[COSTAGLIOLA]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells]]></article-title>
<source><![CDATA[Immunol Lett.]]></source>
<year>2005</year>
<volume>99</volume>
<page-range>198-208</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TEO]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[AZWRA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[JONES]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[GAZZARD]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[NELSON]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain--Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection]]></article-title>
<source><![CDATA[J HIV Ther.]]></source>
<year>2007</year>
<volume>12</volume>
<page-range>62-63</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FUJISAKI]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[KAMI]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[MURASHIGE]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[KISHI]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[HORI]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[CHIZUKA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barre syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell transplantation]]></article-title>
<source><![CDATA[Bone Marrow Transplant.]]></source>
<year>2006</year>
<volume>37</volume>
<page-range>617-619</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PILIERO]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[FISH]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[PRESTON]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[CUNNINGHAM]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[KINCHELOW]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[SALGO]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barré syndrome associated with immune reconstitution]]></article-title>
<source><![CDATA[Clin Infect Dis.]]></source>
<year>2003</year>
<volume>36</volume>
<page-range>e1111-114</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
